Restenosis: An overview

Frontiers of Radiation Therapy and Oncology

Volumn 35, Issue , 2001, Pages 147-171

  Casterella, Peter J ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORONARY ARTERY DISEASE; GENE THERAPY; GRAFT OCCLUSION; HUMAN; PATHOPHYSIOLOGY; RECURRENT DISEASE; REVIEW; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY DISEASE; GENE THERAPY; GRAFT OCCLUSION, VASCULAR; HUMANS; RECURRENCE; STENTS;

EID: 0035222198     PISSN: 00719676     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000061274     Document Type: Article

References (52)

1. Gruentzig AR, Senning A, Siegenthaler WE: Non-operative dilatation of coronary artery stenosis: Percutaneous transluminal coronary angioplasty. N Engl J Med 1979;301:61-68.
2. Holmes DR Jr, Vliestra RE, Smith HC, et al: Restenosis after percutaneous transluminal coronary angioplasty (PTCA): A report from the PTCA Registry of the National Heart, Lung and Blood Institute. Am J Cardiol 1984;53(suppl):77C-81C.
3. Golfsauner-Wolf M, Moliterno DJ, Lincoff AM, Topol EJ: Restenosis - An open file. Clin Cardiol 1996;19:347-356.
4. Detre K, Holubkov R, Kelsey S: Percutaneous transluminal angioplasty in 1985-1986 and 1971-1981: The National Heart, Lung and Blood Institute Registry. N Engl J Med 1988;318:265-270.
5. Gilbert SP, Weintraub WS, Talley JD, Boccuzzi SJ, for the Lovastatin Restenosis Trial Group. The cost of restenosis (Lovastin Restenosis Trial). Am J Cardiol 1996;77:196-199.
6. Weintraub WS: Evaluating the cost of therapy for restenosis: Considerations for brachytherapy. Int J Radiat Oncol Biol Phys 1996;36:949-958.
7. Kuntz RE, Gibson CM, Nobuyoshi M, Baim DS: Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. J Am Coll Cardiol 1993;21:15-25.
8. Hirschfeld JW Jr, Schwartz JS, Jugo R, MacDonald RG, et al: The M-Heart Investigators: Restenosis after coronary angioplasty: A multivariate statistical model to relate lesion and procedure variables to restenosis. J Am Coll Cardiol 1991;18:647-656.
9. Nobuyoshi M, Kimura T, Nosaka H: Restenosis after successful percutaneous transluminal coronary angioplasty: Serial angiographic follow-up of 229 patients. J Am Coll Cardiol 1988;12:616.
10. Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ: Abrupt vessel closure complicating coronary angioplasty: Clinical, angiographic therapeutic profile. J Am Coll Cardiol 1992;19:926-935.
11. Detre KM, Holmes DR Jr, Holubkov R, et al: Incidence and consequences of periprocedural occlusion. The 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1990;82:739-750.
12. Glagov S, Weisenberg E, Zairns CK, et al: Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987;316:1371-1375.
13. Post M, Borst C, Kuntz RE: The relative importance of arterial remodeling compared with intimal hyperplasia in lumen renarrowing after balloon angioplasty. A study in the normal rabbit and the hypercholesterolemic Yucatan micropig. Circulation 1994;89:2816-2821.
14. Kakuta T, Currier J, Haudenschild CC, et al: Differences in compensatory vessel enlargement, not intimal formation account for restenosis after angioplasty in the hypercholesterolemic rabbit model. Circulation 1994;89:2809-2815.
15. Mintz GS, Popma JJ, Pichard AD, et al: Arterial remodeling after coronary angioplasty. A serial intravascular ultrasound study. Circulation 1996;94:35-43.
16. Weintraub WS, Kosinski AS, Brown CL III, King SB III: Can restenosis after coronary angioplasty be predicted from clinical variables? J Am Coll Cardiol 1993;21:6-14.
17. Mintz GS, Popma JJ, Pichard AD, et al: Intravascular ultrasound predictors of restenosis after percutaneous transcatheter coronary revascularization. J Am Coll Cardiol 1996;27:1678-1687.
18. Kuntz RE, Safian RD, Carrozza JP, Fishman RF, Mansour M, Baim DS: The importance of acute luminal diameter in determining restenosis after coronary atherectomy or stenting. Circulation 1992;86:1827-1835.
19. Fischman DL, Leon MB, Baim DS, et al: A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
20. Serruys PW, de Jaegere P, Kiemeneij F, et al: A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-495.
21. Erbel R, Haude M, Hopp HW, et al: REstenosis STent (REST) Study: Randomized trial comparing stenting and balloon angioplasty for treatment of restenosis after balloon angioplasty. N Engl J Med 1998;339:1672-1678.
22. Mintz GS, Hoffmann R, Mehran R, et al: In-stent restenosis: The Washington Hospital Center experience. Am J Cardiol 1998;81(7A):7E-13E.
23. Edelman ER, Rogers C: Pathobiologic responses to stenting. Am J Cardiol 1998;81:4E-6E.
24. Hoffmann R, Mintz GS, Dussaillant GR, et al: Patterns and mechanisms of in-stent restenosis. Circulation 1996;94:1247-1254.
25. Topol EJ, Califf RM, Weisman HF, et al: Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. Lancet 1994;343:881-886.
26. Ellis SG, Serruys PW, Popma JJ, et al: Can abciximab prevent neointimal proliferation in Palmaz-Schatz stents? The final ERASER results. Circulation 1997;96:I-87.
27. The IMPACT-II Investigators: Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-1428.
28. Gibson CM, Goel M, Cohen DJ, et al: Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. J Am Coll Cardiol 1998;32:28-34.
29. Okamoto S, Inden M, Setsuda M, et al: Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1992;123:1439-1444.
30. Nishikawa H, Ono N, Motoyasu M, et al: Preventive effects of trapidil on restenosis after PTCA (abstract). Circulation 1992;86:I-53.
31. Maresta A, Balducelli M, Cantini L, et al: Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Circulation 1994;90:2710-2715.
32. Tardif JC, Cote G, Lesperance J, Bourassa M, et al, for the Multivitamins and Probucol Study Group. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997;337:365-372.
33. Yokoi H, Daida H, Kuwabara Y, Nishikawa H, et al: Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: The Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol 1997;30:855-862.
34. Setsuda M, Inden M, Hiraoka N, Okamoto S, et al: Probucol therapy in the prevention of restenosis after percutaneous transluminal coronary angioplasty. Clin Ther 1993;15:374-382.
35. Watanabe K, Sekiya M, Ikeda S, Miyagawa M, et al: Preventive effect of probucol on restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1996;132:23-29.
36. O'Keefe JH, Stone GW, McCallister BDJ, Maddex C, et al: Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1996;77:649-652.
37. Ueda K, Tamai H, Hsu Y-S, et al: Efficacy of tranilast on restenosis after coronary angioplasty: Is there any rebound phenomenon after ceasing tranilast at 3 months (abstract)? J Am Coll Cardiol 1995;25:225A.
38. Teirstein PS, Massullo V, Jani S, et al: Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997;336:1697-1703.
39. Waksman R,White LR, Chan RC, et al: Intracoronary c-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation 2000;101:2165-2171.
40. Teirstein PS, Massullo V, Jani S, et al: Three-year clinical and angiographic follow-up after intracoronary radiation. Results of a randomized clinical trial. Circulation 2000;101:360-365.
41. Bailey SR: Local drug delivery: Current applications. Prog Cardiovasc Dis 1997;40:183-204.
42. Steg PG, Feldman LJ: Prospects for gene therapy of postangioplasty restenosis. Adv Nephrol 1997;26:121-131.
43. Mak KH, Topol EJ: Clinical trials to prevent restenosis after percutaneous coronary revascularization. Ann N Y Acad Sci 1997;811:255-288.
44. Morishita R, Gibbons GH, Ellison M, Nakjima L, et al: Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 1993;90:8474-8478.
45. Villa AE, Guzman LA, Poptic EJ, Labhasetwar V, et al: Effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury. Circ Res 1995;76:505-513.
46. Chang MW, Barr E, Seltzer J, et al: Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995;267:518-522.
47. Morishita R, Gibbons GH, Horiuchi M, et al: A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995;92:5855-5859.
48. Branellec D, Pastore C, Dedieu J, et al: A recombinant adenovirus encoding gax can efficiently block vascular smooth muscle cell proliferation (abstract). Circulation 1995;92:I-634A.
49. Guzman RJ, Hirschowitz EA, Brody SL, et al: In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci USA 1994;91:10723-10736.
50. Ohno T, Gordon D, San H, et al: Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994;265:781-784.
51. Lefkovits J, Topol EJ: Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention. Prog Cardiovasc Dis 1997;40:141-158.
52. Popma JJ, Califf RM, Topol EJ: Clinical trials of restenosis after coronary angioplasty. Circulation 1991;84:1426-1436.